(Q36017400)

11 August 2017

The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease (English)

1 reference

11 August 2017

4

Paul M Stewart

0 references

Charles J. Ferro

object named as

Charles J Ferro

series ordinal

5

0 references

Jonathan N Townend

object named as

Jonathan N Townend

series ordinal

6

0 references

Richard P Steeds

series ordinal

2

object named as

Richard P Steeds

1 reference

11 August 2017

3

Colin D Chue

1 reference

11 August 2017

Nicola C Edwards

1

1 reference

PMC publication ID

3370349

11 August 2017

language of work or name

English

0 references

publication date

1 March 2012

1 reference

British Journal of Clinical Pharmacology

11 August 2017

1 reference

11 August 2017

73

1 reference

11 August 2017

3

1 reference

11 August 2017

447-454

1 reference

Serum potassium and outcomes in CKD: insights from the RRI-CKD cohort study

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

The incidence and implications of aldosterone breakthrough

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Adoption of spironolactone therapy for older patients with heart failure and left ventricular systolic dysfunction in the United States, 1998-2001.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Spironolactone use and renal toxicity: population based longitudinal analysis

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Guide to Receptors and Channels (GRAC), 4th Edition

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Pharmacotherapy: Cardiovascular effects of aldosterone blockade in CKD.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Predictors of hyperkalemia risk following hypertension control with aldosterone blockade

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Effectiveness of aldosterone blockade in patients with diabetic nephropathy

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3370349

Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials

23 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21950312

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21950312

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/J.1365-2125.2011.04102.X

1 reference

11 August 2017

1 reference

PMC publication ID

3370349

11 August 2017

PubMed publication ID

21950312

1 reference

PMC publication ID

3370349